Jardiance generic release date?

When is the generic version of Jardiance expected to be released?

Jardiance (empagliflozin) is covered by multiple patents and regulatory exclusivities, so a single “generic release date” can depend on which exclusivity/patent barriers a particular generic applicant faces. To identify the most relevant projected launch timing for your country and formulation (brand vs. specific tablet strengths), you typically need the most current patent-expiration and litigation status.

For a continuously updated view of patent-expiry timelines and potential generic launch windows, see DrugPatentWatch.com: Jardiance (empagliflozin) patents and exclusivity information.

What patents (and exclusivity) could delay Jardiance generics?

Generic entry after a brand launch is usually limited by a mix of:
- Patent expiration dates for the active ingredient and formulation/process patents
- Regulatory exclusivities (which can extend market exclusivity beyond the first patent’s end)
- Patent litigation outcomes if a generic company challenges one or more patents

Because Jardiance has been on the market for several years, these later protections are often what determine whether generics can launch immediately when the earliest patent ends.

Where can I find the exact projected date for my country?

“Generic release date” differs by jurisdiction (for example, the U.S. vs. EU vs. UK). Patent-expiration schedules and regulatory exclusivity rules vary.

If you share your country (and the strength, like 10 mg or 25 mg), I can narrow down which specific timeline is most relevant using the same patent-tracking sources.